Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SANTA BARBARA, Calif. (KEYT) A pilot program that shuttles people of all abilities up and down State Street is being extended. It's called The Loop Shuttle. City leaders said 16,700 people have taken ...
KANNAPOLIS, N.C. — A new walking path has opened in Kannapolis, offering a two-thirds of a mile loop on the sidewalks of Glen Afton Boulevard. The path is part of the Loop the Loop program, which ...
Sound Judgment: “A lot of people didn’t use our products for protection, but for comfort,” says, Loop CEO Dimitri O (right) with cofounder Maarten Bodewes, “comfort that they get through control over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback